(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
(PRESS RELEASE) VEVEY, 14-Oct-2020 — /EuropaWire/ — Nestlé has successfully closed the acquisition of biopharmaceutical company, Aimmune Therapeutics, Inc. (Nasdaq: AIMT). The company which specializes in developing and bringing new treatments to people with potentially life-threatening food allergies joins Nestlé … Read the full press release
Posted in Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged acquisition, Aimmune Therapeutics, allergic reactions, allergies, AlMab7195, anaphylaxis, Andrew Oxtoby, Arachis hypogaea, asthma, EM, Eosinophilic Gastrointestinal Disease, European Medicines Agency, FDA, Greg Behar, monoclonal antibody, Nestlé, Nestlé Health Science, NHSc, oral immunotherapy, PALFORZIA®, Peanut Allergen Powder-dnfp, Pharmaceutical, science-bassed nutritional solutions, Swiss Agency for Therapeutic Products, SwissMedic, treating peanut allergy
LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
